CA3177438A1 - Clofazimine composition and method for the treatment or prophylaxis of viral infections - Google Patents
Clofazimine composition and method for the treatment or prophylaxis of viral infections Download PDFInfo
- Publication number
- CA3177438A1 CA3177438A1 CA3177438A CA3177438A CA3177438A1 CA 3177438 A1 CA3177438 A1 CA 3177438A1 CA 3177438 A CA3177438 A CA 3177438A CA 3177438 A CA3177438 A CA 3177438A CA 3177438 A1 CA3177438 A1 CA 3177438A1
- Authority
- CA
- Canada
- Prior art keywords
- clofazimine
- pharmaceutically acceptable
- composition
- inhalable
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018677P | 2020-05-01 | 2020-05-01 | |
| US63/018,677 | 2020-05-01 | ||
| PCT/US2021/030155 WO2021222740A1 (en) | 2020-05-01 | 2021-04-30 | Clofazimine composition and method for the treatment or prophylaxis of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177438A1 true CA3177438A1 (en) | 2021-11-04 |
Family
ID=78332269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177438A Pending CA3177438A1 (en) | 2020-05-01 | 2021-04-30 | Clofazimine composition and method for the treatment or prophylaxis of viral infections |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230248722A1 (enExample) |
| EP (1) | EP4142691A4 (enExample) |
| JP (1) | JP7893751B2 (enExample) |
| KR (1) | KR20230005937A (enExample) |
| CN (1) | CN115666510A (enExample) |
| AU (1) | AU2021263580B2 (enExample) |
| BR (1) | BR112022022081A2 (enExample) |
| CA (1) | CA3177438A1 (enExample) |
| WO (1) | WO2021222740A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023102363A1 (en) * | 2021-11-30 | 2023-06-08 | Mannkind Corporation | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers |
| JP2025529312A (ja) * | 2022-09-06 | 2025-09-04 | マンカインド コーポレイション | 非結核性抗酸菌症を処置するための方法 |
| WO2025091042A1 (en) * | 2023-10-27 | 2025-05-01 | Mannkind Corporation | Methods for treating non-tuberculous mycobacterial infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| KR101822208B1 (ko) * | 2009-11-02 | 2018-01-25 | 맨카인드 코포레이션 | 약학적 조성물을 극저온 과립화하는 장치 및 방법 |
| BR112015023168B1 (pt) * | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| RU2016143590A (ru) * | 2014-04-08 | 2018-05-11 | Арадайм Корпорейшн | Липосомальные композиции ципрофлоксацина, обладающие активностью против нетуберкулезных микробактерий |
| SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
| WO2016123530A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Compositions and methods for delivering pharmaceutical agents |
| CN108853106B (zh) | 2017-05-09 | 2021-02-02 | 中国食品药品检定研究院 | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 |
| EP3691646A4 (en) | 2017-10-02 | 2021-06-30 | Board of Regents, The University of Texas System | CLOFAZIMIN INHALABLE COMPOSITION AND METHOD OF USE |
| WO2019110099A1 (en) | 2017-12-06 | 2019-06-13 | Qrumpharma Inc. | Inhalable clofazimine formulation |
| CA3109572A1 (en) | 2018-08-23 | 2020-02-27 | Mannkind Corporation | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
-
2021
- 2021-04-30 JP JP2022566323A patent/JP7893751B2/ja active Active
- 2021-04-30 CA CA3177438A patent/CA3177438A1/en active Pending
- 2021-04-30 BR BR112022022081A patent/BR112022022081A2/pt unknown
- 2021-04-30 WO PCT/US2021/030155 patent/WO2021222740A1/en not_active Ceased
- 2021-04-30 KR KR1020227041996A patent/KR20230005937A/ko active Pending
- 2021-04-30 AU AU2021263580A patent/AU2021263580B2/en active Active
- 2021-04-30 CN CN202180031573.9A patent/CN115666510A/zh active Pending
- 2021-04-30 EP EP21796019.4A patent/EP4142691A4/en active Pending
- 2021-04-30 US US17/996,706 patent/US20230248722A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021263580A1 (en) | 2022-11-24 |
| JP7893751B2 (ja) | 2026-07-22 |
| US20230248722A1 (en) | 2023-08-10 |
| JP2023524064A (ja) | 2023-06-08 |
| CN115666510A (zh) | 2023-01-31 |
| BR112022022081A2 (pt) | 2022-12-13 |
| WO2021222740A1 (en) | 2021-11-04 |
| AU2021263580B2 (en) | 2026-08-06 |
| EP4142691A4 (en) | 2024-05-15 |
| EP4142691A1 (en) | 2023-03-08 |
| KR20230005937A (ko) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004535454A (ja) | エーロゾル化用に至適化されたトブラマイシン製剤 | |
| AU2021263580A1 (en) | Clofazimine composition and method for the treatment or prophylaxis of viral infections | |
| EP4232073B1 (en) | New dosage regimen for inhaled vasoactive intestinal polypeptide | |
| JP2008503586A (ja) | アンフォテリシンｂを含む組成物、方法、およびシステム | |
| EP4138832A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| AU2009331277B2 (en) | Dry powder pharmaceutical composition for inhalation | |
| US20250228779A1 (en) | Method and composition for treating pulmonary fibrosis | |
| AU2003243191B2 (en) | Formulations limiting spread of pulmonary infections | |
| WO2015027848A1 (zh) | 含有帕拉米韦和/或其衍生物制剂的给药方法 | |
| CN102716105B (zh) | 干扰素α的干粉吸入剂 | |
| JPH10500966A (ja) | 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物 | |
| MX2013004030A (es) | Composicion farmaceutica a base de denufosol para tratar fibrosis quistica. | |
| Thai et al. | Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims | |
| HK40083799A (en) | Clofazimine composition and method for the treatment or prophylaxis of viral infections | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| Balducci et al. | Drug delivery strategies for pulmonary administration of antibiotics | |
| JP6908523B2 (ja) | ネブライザー用組成物 | |
| WO2025240845A1 (en) | Method and composition for treating lung diseases | |
| CN114129546A (zh) | 一种吸入用药物组合物 | |
| CN119486717A (zh) | 治疗肺疾病的方法和组合物 | |
| WO2015027847A2 (zh) | 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法 | |
| Abdalaziz et al. | Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250423 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250619 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250619 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260424 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260723 |